Gene Editing Medicines: Getting Them to Families in Need
Here’s a breakdown of the key points from the provided text, focusing on the challenges and potential paths forward for gene editing therapies:
Main Challenges:
* High Cost & Long Wait Times for Viral Delivery: Creating customized viruses to deliver gene editors (like CRISPR) is incredibly expensive ($2 million per batch) and takes over a year. This isn’t scalable for personalized medicine where each patient needs a unique editor.
* Regulatory Hurdles: Current regulations are designed for treating thousands of patients, which is impractical for rare diseases where patients are few and time is critical. A small child needing immediate treatment can’t wait for a manufacturing process geared towards large-scale production.
* Lack of For-Profit Investment: There’s a current slowdown in commercial investment in genetic disease research, notably outside of areas like lung diseases.
Viable Paths Forward (Short-Term):
* Antisense Oligonucleotides: Using these to increase the expression of a faulty gene.
* Gene Addition Therapy: Using AAV (a type of virus) to add a working copy of a gene.This is more scalable as the same AAV can be used for many patients.
* Non-Viral Delivery (specific Tissues): For some tissues like the lungs, non-viral delivery methods (like LNP-mRNA) are showing promise and are more clinically actionable.
Longer-Term Solutions & Needed Changes:
* “Master Clinical Trial Protocol” & “Platform Approach”: Following the model developed by CHOP-penn, IGI-UCSF, and others – a standardized trial design combined with streamlined manufacturing and risk reduction for on-demand CRISPR.
* “Benefit-Risk Commensurate” Manufacturing: Developing faster, smaller-scale manufacturing processes (like the IGI/Danaher collaboration) that are appropriate for individual patients and urgent situations.
* FDA Regulatory Flexibility: The FDA needs to adopt a more flexible approach, allowing for accelerated approval pathways based on a “plausible mechanism” rather than requiring data from large-scale trials that aren’t feasible for rare diseases.
Overall Message:
The technology for gene editing is rapidly improving, but regulatory and manufacturing bottlenecks are preventing these possibly life-saving therapies from reaching patients who need them now. A shift in regulatory thinking and increased investment are crucial to unlock the full potential of gene editing for rare and severe diseases.